Rhythm management in atrial fibrillation - With a primary emphasis on pharmacologic therapy: Part 3

PACE - Pacing and Clinical Electrophysiology

Volumn 21, Issue 5, 1998, Pages 1133-1145

  Kassotis, John ^a   Costeas, Constantinos ^a   Blitzer, Mark ^a   Reiffel, James A ^a  

^a NONE

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Cardioversion; Rate control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ADULT; AGED; AGRANULOCYTOSIS; ANTICOAGULATION; CARDIOVERSION; CLINICAL ARTICLE; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; MALE; REVIEW; SINUS RHYTHM; SKIN DISEASE; THROMBOCYTOPENIA;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; HEART RATE; HUMANS; PATIENT CARE PLANNING; RISK FACTORS;

EID: 0031965860     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1998.tb00160.x     Document Type: Review

References (64)

1. Crijns HJ, Van Gelder IC, Van Gilst WH, et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68:335-341.
2. Juul-Moller S, Edvardsson AN, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82:1932-1939.
3. Boissel JP, Wolfe E, Gillet J, et al. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981; 2:49-55.
4. Sodermark T, Yansson B, Olson A, et al. Effect of quinidine on maintaining sinus rhythm after cardioversion of atrial fibrillation or flutter. A multicenter study from Stockholm. Br Heart J 1975; 37:486-492.
5. Hillestad L, Bjerkerlund C, Dale J, et al. Quinidine in maintenance of sinus rhythm after electroversion of chronic atrial fibrillation. A control study. Br Heart J 1971; 33:518-521.
6. Grande P, Sonne B, Pedersen A. A controlled study of digoxin and quinidine in patients DC reverted from atrial fibrillation to sinus rhythm. Circulation 1986; 74:II-101.
7. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984; 65:367-369.
8. Zehender M, Hohnloser S, Muller B. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2 year follow-up. J Am Coll Cardiol 1992; 19:1054-1059.
9. Rasmussen K, Andersen A, Abrahamsen A, et al. Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. Eur Heart J 1988; 9:I-52.
10. Karlson BW, Torstensson I, Abjorn C, et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9:284-290.
11. Crijns HJGM, Gosselink ATM, Lie KI. Propafenone versus disopyramide for the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation: A randomized double-blind study. Cardiovasc Drugs Ther 1996; 2:145-152.
12. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558-563.
13. Antman EM, Beamer AD, Cantillon C, et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12:1011.
14. Van Gelder IV, Crijns HJGM, Van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64:1317-1321.
15. Zarembski DG, Nolan PE, Slack MD, et al. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885-1891.
16. Chun SH, Sager PT, Stevenson WG, et al. Long term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76:47-50.
17. Gold RL, Haffaajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57:124-127.
18. Szyszka A, Paluszkiewicz, Baszynska H, et al. Prophylactic treatment after electroconversion of atrial fibrillation in patients after cardiac surgery - A controlled two-years follow-up study. J Am Coll Cardiol 1993; 21:A-201.
19. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 71:75F-81F.
20. Anderson JL. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: The United States exerience. Am J Cardiol 1992; 70:11A-18A.
21. Chiemienti M, Cullen MT, Casadei G, for the flecainide and propafenone Italian study (FAPIS) investigators. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation; Report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996; 77:60A-65A.
22. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1:1142-1147.
23. Aliot E, Denjoy I, and the Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic atrial fibrillation/flutter. Am J Cardiol 1996; 77:66A-71A.
24. Naccarelli GV, Dorian P, Hohnloser SH, et al, for the flecainide multicenter atrial fibrillation study group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77:53A-59A.
25. Bellandi F, Dabizzi RP, Niccoli L, et al. Propafenone and sotalol: Long term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. G Ital Cardiol 1996; 26:379-390.
26. Anderson JL, Gilbert EM, Albert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo. Circulation 1989; 80:1557-1570.
27. Gaita F, Greco C, Biagioli F, et al. Atrial fibrillation: Propafenone versus quinidine in the long term prophylaxis. Eur Heart J 1989; 10(Suppl):102.
28. Lee Sh, Chen SA, Chiang CE, et al. Comparison of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: A double-blind, randomized trial. J Intern Med 1996; 239:253-260.
29. Clementy J, Dulhoste MN, Laiter C, et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70:44A-49A.
30. Sonnhag C, Kallryd A, Nylander E, et al. Long term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand 1988; 224:563-569.
31. Hammil SC, Wood DL, Osborn MJ, et al. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988; 61:473-474.
32. Leclercq JF, Chouty F, Denjoy J, et al. Flecainide in quinidine resistant atrial fibrillation. Am J Cardiol 1992; 70:62A-65A.
33. Anderson JL, Platt ML, Guarnieri T, et al. Flecainide acetate for paroxysmal supraventricular tachycardias. Am J Cardiol 1994; 74:578-584.
34. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. (The CASCADE Study). Am J Cardiol 1993; 72:280-287.
35. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
36. Julian DG, Camm AJ, Frangia G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. (EMIAT): European Myocardial Infarct Amiodarone Trial. Lancet 1997; 349:662-663.
37. Cairns JA, Connolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations (CAMIAT): Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Lancet 1997; 349:675-682.
38. Levy S, Novella P, Ricard P, et al. Paroxysmal atrial fibrillation: A need for classification. J Cardiovasc Electrophysiol 1995; 6:69-74.
39. Fuller JA, Adams GC, Baxton B. Atrial fibrillation after coronary artery bypass grafting: Is it a disorder of the elderly? J Thorac Cardiovasc: Surg 1989; 97:821-825.
40. Dixon FE, Genton E, Vacek JL, et al. Factors predisposing to supraventricular tachyarrhythmias after coronary artery byapss grafting. Am J Cardiol 1986; 58:476-478.
41. Roffman JA, Feldman A. Digoxin and propranolol in the prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass surgery. Ann Thorac Surg 1981; 31:486-501.
42. Leitch JW, Thomson D, Baird DK, et al. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1990; 100:338-342.
43. Douglas P, Hirshfeld JW Jr, Edmunds H. Clinical correlates of postoperative atrial fibrillation. Circulation 1984; 70:II-165.
44. Chicambaram M, Akhtar MJ, Al-Nozha M, et al. Relationship of atrial fibrillation to significant pericardial effusion in valve-replacement patients. Thorac Cardiovasc Surg 1992; 40:70-73.
45. White HD, Antman GM, Glynn MA, et al. Efficacy and safety of timolol for prevention of supraventricular arrhythmias after coronary artery bypass surgery. Circulation 1984; 70:479-484.
46. Salazar C, Frishman W, Friedman S, et al. Beta-blockade therapy for supraventricular tachyarrhythmias after coronary surgery: A propranolol withdrawal syndrome? Angiology 1979; 30:816-819.
47. Kowey PR, Taylor JE, Rials SJ, et al. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69:963-965.
48. Fahy GJ, Wilkoff BL. Pacing strategies to prevent atrial fibrillation. Cardiol Clin 1996; 14(4):591-596.
49. Cox JL, Boineau J, Schuessler R, et al. Successful surgical treatment of atrial fibrillation: Review and clinical update. JAMA 1991; 266:1976-1980.
50. Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical techniques. J Thorac Cardiovasc Surg 1991; 101:584-592.
51. Cox JL, Boineau JP, Schuessler RB, et al. Five-year experience with the MAZE procedure for atrial fibrillation. Ann Thorac Surg 1993; 56:814-824.
52. Cox JL, Schuessler RB, Lappas DG, et al. An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1966; 224:267-275.
53. Cox JL, Schuessler RB, D'Agostino HJ, et al. The surgical treatment of atrial fibrillation III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101:569-583.
54. Cox JL, Canavan TE, Schuessler RB, et al. The surgical treatment of atrial fibrillation II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101:406-426.
55. Cox JL, Boineau JP, Schuessler RB, et al. Modification of the MAZE procedure for atrial flutter and atrial fibrillation I. Rationale and surgical results. J Thorac Cardiovasc Surg 1995; 110:473-484.
56. Cox JL, Jaquiss RDB, Schuessler RB, et al. Modification of the MAZE procedure for atrial flutter and atrial fibrillation II. Surgical technique of the MAZE III procedure. J Thorac Cardiovasc Surg 1995; 110:485-495.
57. Guiraudon GM. Surgical treatment of atrial fibrillation. Herz 1993; 18:51-59.
58. Itoh T, Okamoto H, Nimi T, et al. Left atrial function after Cox's MAZE operation concomitant with mitral valve operation. Ann Thorac Surg 1995; 60:354-360.
59. Kosaka Y, Kawaguchi AT, Isobe F, et al. Modified MAZE procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Circulation 1995; 92:II-359-II-364.
60. Sandoval N, Valexco VM, Orjuela H, et al. Concomitant mitral valve or atrial septal defect surgery and the modified Cox-MAZE procedure. Am J Cardiol 1996; 77:591-596.
61. Sueda T, Nagato H, Shikata H, et al. Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. Ann Thorac Surg 1996; 62:1796-1800.
62. Haissaguerre M, Gencel L, Fischer B, et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5:1045-1052.
63. Haissaguerre M, Marcus FI, Fischer B, et al. Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation. Report of three cases. J Cardiovasc Electrophysiol 1994; 5:743-751.
64. Haissaguerre M, Jais P, Shah DC, et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7:1132-1144.